Addressing methodological considerations in the assessment of the effect of SGLT2 inhibitors and GLP-1 receptor agonists on diabetic eye complications. Reply to Tsai Y-H, Hemphill NO, Kurth T
Diabetologia. 2025 Jan;68(1):249-250.
doi: 10.1007/s00125-024-06314-1.
Epub 2024 Nov 7.
1 Department of Cardiovascular & Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
2 Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Science, School of Biological Sciences, Faculty of Biological Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
3 TriNetX LLC, Cambridge, MA, USA.
4 Liverpool Centre for Cardiovascular Science at the University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.
5 Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
6 Faculty of Life Science and Medicine, King's College London, London, UK.
7 King's Ophthalmology Research Unit (KORU), King's College Hospital, London, UK.
8 Department of Medicine, University Hospital Aintree, Liverpool University NHS Foundation Trust, Liverpool, UK.
9 Department of Cardiovascular & Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK. uazman.alam@liverpool.ac.uk.
10 Liverpool Centre for Cardiovascular Science at the University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK. uazman.alam@liverpool.ac.uk.
11 Department of Medicine, University Hospital Aintree, Liverpool University NHS Foundation Trust, Liverpool, UK. uazman.alam@liverpool.ac.uk.
12 Visiting Fellow, Centre for Biomechanics and Rehabilitation Technologies, Staffordshire University, Stoke-on-Trent, UK. uazman.alam@liverpool.ac.uk.